This article explores lab data integrity violation trends, as well as a sampling of the latest technologies that can help avoid them.
Amber Lowry
Advertisement
Amber Lowry is an associate editor at UBM plc.
Articles by Amber Lowry
This article explores some of the challenges, services, and technologies that go into ensuring that vaccines are properly temperature controlled and maintain product integrity for delivery to patients.
Advertisement
Latest Updated Articles
Cold Chain: Delivering Vaccines to PatientsNovember 15th 2017
Maintaining Lab Data IntegrityFebruary 1st 2018
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
3
AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform
4
The BioPharm Brief: Base Editing Hits Its Mark in Sickle Cell, a Phase 3 Win in Sjögren’s, and Off-the-Shelf CAR-T in Lupus
5